Imaging: Advancing Biomarker Research for Alzheimer's Disease Diagnosis 

Alzheimer's disease (AD) presents a significant challenge, not only for those diagnosed but also for their families and healthcare providers. As the global population ages, the urgency for effective diagnostic tools and treatment strategies intensifies.

The Bio-Hermes study, sponsored by the Global Alzheimer's Platform Foundation (GAP) and supported by IXICO as imaging partner, offers valuable insights into emerging possibilities for efficient and reliable determination of a subject’s amyloid status, a key part of diagnostic and trial recruitment criteria.

Two-Stage Screening Process: The study employs a two-stage screening process where initial blood-based biomarker (BBM) tests are followed by amyloid positron emission tomography (PET) scans for ambiguous cases. This approach enhances trial efficiency by reducing screen failure rates and improving the identification of suitable candidates for clinical trials.

By examining the interplay between imaging and BBMs, we highlight how BBMs offer a more accessible, less invasive, and cost-effective alternative where appropriate, while acknowledging the need for a gold-standard assessment from PET in certain cases.

Read the full editorial here

---